Dermatological Drugs Market Share, Growth, Trends | Report 2022-2030
The global dermatological drugs market was surpassed at USD 17.1 billion in 2021 and is expected to hit around USD 36.5 billion by 2030, growing at a CAGR of 8.79% from 2022 to 2030.
The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases, nutritional deficiency due to unhealthy food habits, increasing awareness when it comes to lifestyle diseases, and increasing pollution levels, and lack of immunity in the population. Additionally, the rising per capita income and the increasing purchasing power are the driving forces in this market.
The acne segment is expected to expand with a CAGR of 10.5% from 2022 to 2028. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts. Additionally, infected hair follicles cause acne, which starts from the skin’s pores. Acne causes bumps on the face, shoulders, chest, and back in the form of pimples, blackheads, and whiteheads. Acne can be cured, and the appearance of the skin can be improved with effective treatment from dermatologists, contributing to the dermatological drug market.
North America held the largest revenue share of more than 35% in 2021. The U.S. is positively contributing to the growth of the regional market. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth. This region is one of the promising regions to launch new technology in terms of healthcare infrastructure and advanced research and development activities that help innovate and produce the most appropriate drugs to cure cancer. It is observed that in the region, there is a rapid shift in the healthcare industry to consumer-driven from traditional treatment for providing diagnosis and provision-based health services. Additionally, ease of availability of drugs and reimbursement policies for the patient in the healthcare industry contributes to driving the market in the region.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 17.1 billion |
| Revenue Forecast by 2030 | USD 36.5 billion |
| Growth rate from 2022 to 2030 | CAGR of 8.79% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Indication, region |
| Companies Covered | Novartis AG, Amgen Inc, AbbVie Inc, Johnson & Johnson, Leo Pharma A/S, Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca plc, Pfizer Inc, Merck KGaA |
Indication Insights
The psoriasis segment dominated the market with a revenue share of more than 35.0% in 2021 and is expected to expand with the highest CAGR of 11.5% from 2022 to 2028. Psoriasis is caused by the immune system mistakenly attacking healthy skin cells. Psoriasis is not a contagious disease. The disease causes swollen fingers and toes, foot pain, lower back pain, nail changes, and eye inflammation. Psoriasis can be triggered by stress, skin injury, infections, some drugs, and heavy drinking. Psoriasis is found in all age groups but is majorly seen in adults and contributes to the global dermatology drug revenue.
The alopecia segment is likely to expand with the second-highest CAGR of 10.9% from 2022 to 2028. Alopecia caused due to the body’s immune system attacking hair follicles resulting in hair loss. Alopecia is an autoimmune disorder that results in hair coming out. Both men and women suffer from Alopecia due to an imbalance of hormones, hair care treatments, scalp infections, and possible side effects of some medications. Additionally, hereditary hair loss is the most common cause of hair loss globally. Citizens are careful about hair loss and visit hospitals for diagnosis. Hair loss requires ongoing treatments for a long period and contributes to the market growth rate.
Regional Insights
Asia Pacific is likely to expand at the highest CAGR of 12.2% from 2022 to 2028. Countries such as China and India, with the largest populations in the world, are expected to have many patients with skin diseases during the forecast period. Continuous improvement in the life science industry and health services and the awareness of skin diseases and their treatment are factors contributing to the highest growth of this market. Moreover, increasing incomes and the purchasing power of citizens are witnessing a significant growth rate in this market.
Europe held the second-largest revenue share of more than 30.0% in 2021 and is expected to continue with a growth of 11% during the forecast period. Factors such as increasing large investment in the healthcare sector, greater prevalence of healthcare insurance among the masses, and supportive regulatory frameworks of the pharmaceutical industry in this region are attributed to the market revenue generation.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1.Raw Material Procurement Analysis
4.3.2.Sales and Distribution Channel Analysis
4.3.3.Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatological Drugs Market
5.1.COVID-19 Landscape: Dermatological Drugs Industry Impact
5.2.COVID 19 - Impact Assessment for the Industry
5.3.COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1.Market Drivers
6.1.2.Market Restraints
6.1.3.Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1.Bargaining power of suppliers
6.2.2.Bargaining power of buyers
6.2.3.Threat of substitute
6.2.4.Threat of new entrants
6.2.5.Degree of competition
Chapter 7. Competitive Landscape
7.1.1.Company Market Share/Positioning Analysis
7.1.2.Key Strategies Adopted by Players
7.1.3.Vendor Landscape
7.1.3.1.List of Suppliers
7.1.3.2.List of Buyers
Chapter 8. Global Dermatological Drugs Market, By Indication
8.1. Dermatological Drugs Market, by Indication Type, 2020-2027
8.1.1.Acne
8.1.1.1.Market Revenue and Forecast (2016-2027)
8.1.2.Psoriasis
8.1.2.1.Market Revenue and Forecast (2016-2027)
8.1.3.Rosacea
8.1.3.1.Market Revenue and Forecast (2016-2027)
8.1.4.Alopecia
8.1.4.1.Market Revenue and Forecast (2016-2027)
8.1.5.Others
8.1.5.1.Market Revenue and Forecast (2016-2027)
Chapter 9. Global Dermatological Drugs Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1.Market Revenue and Forecast, by Indication (2016-2027)
9.1.2.U.S.
9.1.3.Rest of North America
9.1.3.1.Market Revenue and Forecast, by Indication (2016-2027)
9.2. Europe
9.2.1.Market Revenue and Forecast, by Indication (2016-2027)
9.2.2.UK
9.2.2.1.Market Revenue and Forecast, by Indication (2016-2027)
9.2.3.France
9.2.3.1.Market Revenue and Forecast, by Indication (2016-2027)
9.2.4.Rest of Europe
9.2.4.1.Market Revenue and Forecast, by Indication (2016-2027)
9.3. APAC
9.3.1.Market Revenue and Forecast, by Indication (2016-2027)
9.3.2.India
9.3.2.1.Market Revenue and Forecast, by Indication (2016-2027)
9.3.3.China
9.3.3.1.Market Revenue and Forecast, by Indication (2016-2027)
9.3.4.Japan
9.3.4.1.Market Revenue and Forecast, by Indication (2016-2027)
9.3.5.Rest of APAC
9.3.5.1.Market Revenue and Forecast, by Indication (2016-2027)
9.4. MEA
9.4.1.Market Revenue and Forecast, by Indication (2016-2027)
9.4.2.GCC
9.4.2.1.Market Revenue and Forecast, by Indication (2016-2027)
9.4.3.North Africa
9.4.3.1.Market Revenue and Forecast, by Indication (2016-2027)
9.4.4.South Africa
9.4.4.1.Market Revenue and Forecast, by Indication (2016-2027)
9.4.5.Rest of MEA
9.4.5.1.Market Revenue and Forecast, by Indication (2016-2027)
9.5. Latin America
9.5.1.Market Revenue and Forecast, by Indication (2016-2027)
9.5.2.Brazil
9.5.2.1.Market Revenue and Forecast, by Indication (2016-2027)
9.5.3.Rest of LATAM
9.5.3.1.Market Revenue and Forecast, by Indication (2016-2027)
Chapter 10. Company Profiles
10.1.Novartis AG
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2.Amgen Inc
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3.AbbVie Inc
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4.Johnson & Johnson
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5.Leo Pharma A/S
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6.Eli Lilly and Company
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7.GlaxoSmithKline Plc
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8.AstraZeneca plc
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9.Pfizer Inc
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10.Merck KGaA
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1.Primary Research
11.2.Secondary Research
11.3.Assumptions
Chapter 12. Appendix
12.1.About Us
12.2.Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers